Recce Pharmaceuticals Ltd (RECEF)
OTCMKTS · Delayed Price · Currency is USD
0.2200
-0.2800 (-56.00%)
At close: Jun 24, 2025
Recce Pharmaceuticals Revenue
In the fiscal year ending June 30, 2025, Recce Pharmaceuticals had annual revenue of 7.51M AUD with 49.33% growth. Recce Pharmaceuticals had revenue of 562.52K in the half year ending June 30, 2025, a decrease of -87.11%.
Revenue
7.51M AUD
Revenue Growth
+49.33%
P/S Ratio
24.58
Revenue / Employee
n/a
Employees
n/a
Market Cap
121.02M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 7.51M | 2.48M | 49.33% |
| Jun 30, 2024 | 5.03M | 663.14K | 15.19% |
| Jun 30, 2023 | 4.37M | 1.28M | 41.50% |
| Jun 30, 2022 | 3.08M | 1.45M | 88.41% |
| Jun 30, 2021 | 1.64M | 515.66K | 45.97% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| Arch Biopartners | 198.11K |